Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VS-214
- Development stage
- Preclinical
- Lead developer
- Vasa Therapeutics
- Modality
- Peptides
01
Overview
VS-214 is a long-acting apelin analog being developed as a peptide therapeutic for the treatment of peripheral arterial disease (PAD) and various rare neuromuscular diseases. Developed by Vasa Therapeutics, it acts as an agonist of the apelin receptor, a G protein-coupled receptor that modulates cardiovascular and musculoskeletal signaling pathways. Preclinical evidence suggests that VS-214 can increase muscle strength and endurance, preserve muscle function, and enhance cardiac output. Its targeted indications include facioscapulohumeral muscular dystrophy (FSHD), spinal muscular atrophy (SMA), spinal cord injury, and sarcopenia. The drug is currently in preclinical development, with clinical trials expected to commence in 2026.
- Other names
- long-acting apelin analogapelin receptor agonist
02
Targets
Beyond the preview
Go deeper on VS-214.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VS-214.